PCM
BDTX icon

Penserra Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History

Penserra Capital Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-830
Closed -$7K – 1387
2021
Q3 		$7K Buy
830
+5
+0.6% +$49 ﹤0.01% 1389
2021
Q2 		$10K Buy
825
+5
+0.6% +$99 ﹤0.01% 1270
2021
Q1 		$19K Sell
820
-5
-0.6% -$135 ﹤0.01% 976
2020
Q4 		$26K Buy
+825
New +$27.1K ﹤0.01% 813

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Penserra Capital Management's BDTX Position: Q4 2021 in Review

Penserra Capital Management sold out of Black Diamond Therapeutics (BDTX) in Q4 2021, closing a stake of 830 shares — an estimated $7K sold.

Penserra Capital Management first reported a position in BDTX in Q4 2020 and held it in 4 quarters. The position peaked at $26K in Q4 2020. 95 funds tracked by Wall St. Rank hold BDTX as of Q4 2021.

  • Penserra Capital Management reported no remaining Black Diamond Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 830 Black Diamond Therapeutics shares in Q4 2021, an estimated $7K.
  • Penserra Capital Management first reported a position in Black Diamond Therapeutics in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's Black Diamond Therapeutics position peaked at $26K in Q4 2020.
  • 95 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.